CSIMarket
 
Rvl Pharmaceuticals Plc  (RVLP)
Other Ticker:  
 
 

Rvl Pharmaceuticals Plc Growth Comparisons

Select each growth Category to receive further Information



RVLP Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) -13.45 % -8.08 % -9.13 % -2.32 %
Q / Q Revenue Growth (Q2 MRQ) -17.21 % 0.87 % -5.54 % 1.4 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 95.7 % -4.65 % -2.5 % %
Seq. Revenue Growth (for 12 months ending Q2 TTM) -3.06 % -2.16 % -2.4 % -0.58 %
Revenue 5 Year Average Growth - 14.14 % 10.74 % 11.13 %


RVLP's Growth Comparisons in II. Quarter 2023




Rvl Pharmaceuticals Plc reported sharp sales fall by -13.45% from the same quarter a year ago, in the second quarter 2023, despite the minor sales decline in the Major Pharmaceutical Preparations industry by -8.08%, and underperformed the -9.13% Revenue decrease in the Healthcare sector. Weak second quarter sales, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Rvl Pharmaceuticals Plc results which underperformed overall market.

Comparing company's Revenue to the first quarter results, sales were lower by -17.21% . On the annual basis, average annual sales growth for Rvl Pharmaceuticals Plc is %, while S & P 500's including only Businesses with the second quarter 2023 results, average yearly sales growth is 11.13% over the past five years.


Growth Rates of RVLP's Income in the second quarter 2023


RVLP Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -62.98 % -54.13 % -12.34 %
Seq. Operating Income Change (Q2 MRQ) - -59.73 % -56.63 % -3.61 %
Y / Y Operating Income Growth (Q2 TTM) - -15.07 % -20.93 % -6.36 %
Seq. Operating Income Growth (Q2 TTM) - -15.13 % -11.86 % -3.39 %
Operating Income 5 Year Avg. Change - 33.52 % 10.15 % 10.86 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -79.12 % -95.28 % -11.53 %
Seq. Income from Cont. Ops. Change (Q2 MRQ) - -56.3 % -94.97 % -5.24 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -41.86 % -44.68 % -8.47 %
Seq. Income from Cont. Ops. Change (Q2 TTM) - -22.29 % -20.12 % -3.25 %
Income from Cont. Ops. 5 Year Avg. Change - 57.24 % 23.15 % 2.84 %

RVLP Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -79.2 % -95.23 % -9.7 %
Q / Q Net Income Growth (Q2 MRQ) - -56.75 % -94.91 % -3.66 %
Y / Y Net Income Change (Q2 TTM) - -39.86 % -42.75 % -8.38 %
Seq. Net Income Change (Q2 TTM) - -21.79 % -19.69 % -2.75 %
Net Income 5 Year Avg. Growth - 57.4 % 23.18 % 3.12 %

RVLP's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -84.11 % -95.28 % -11.53 %
Seq. EPS from Cont. Ops. Change (Q2 MRQ) - -66.41 % -94.97 % -5.24 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Seq. EPS from Cont. Ops. Change (Q2 TTM) - - - 31261.33 %
EPS from Cont. Ops. 5 Year Avg. Growth - 32.23 % 23.15 % 2.84 %



RVLP EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -84.17 % -95.23 % -9.7 %
Q / Q EPS Net Growth (Q2 MRQ) - -66.76 % -94.91 % -3.66 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 21943.44 %
Seq. EPS Net Change (for 12 months ending Q2 TTM) - - - 26894.53 %
EPS Net 5 Year Avg. Change - 57.4 % 23.18 % 3.12 %



Rvl Pharmaceuticals Plc reported bottom-line of $ -0.24 in the second quarter, compare to $ -0.14 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -84.17%, while Healthcare sector decreased by -95.23%, and overall market declined by -9.7%.

Comparing the company's EPS to the first quarter results, income per share were lower by -17.21% . On the annual basis, average annual income per share growth for Rvl Pharmaceuticals Plc is %, while S & P 500's including only Businesses with the second quarter 2023 financial reports, average yearly income per share growth is 3.12% over the past five years.

RVLP Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - -36.38 % -17.96 % -21.9 %
Seq. Free Cash Flow Change (Q2 MRQ) - 11.79 % 39.54 % 98.37 %
Y / Y Free Cash Flow Change (Q2 TTM) - -20 % -16.19 % -12.2 %
Seq. Free Cash Flow Change (Q2 TTM) - -7.36 % -3.37 % -8.31 %
Free Cash Flow 5 Year Avg. Change - 27.42 % 18.45 % 23.3 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - -
Seq. Net Cash Flow Change (Q2 MRQ) - - - -
Y / Y Net Cash Flow Change (Q2 TTM) - - - -
Seq. Net Cash Flow Change (Q2 TTM) - - 18.8 % -
Net Cash Flow 5 Year Avg. Change - - 0.72 % 48.8 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) - 12.44 % 5.75 % 12.04 %
Seq. Capital Expenditures Change (Q2 MRQ) -19.79 % -0.27 % -1.34 % 4.81 %
Y / Y Capital Expenditures Change (Q2 TTM) 648.18 % 13.03 % 7.12 % -27.19 %
Seq. Capital Expenditures Change (Q2 TTM) 51.55 % 0.63 % 0.7 % -13.82 %
Capital Expenditures 5 Year Avg. Change - 13.29 % 9.25 % 8.65 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com